Kedrion Biopharma is proud to celebrate its 20th anniversary.
Twenty years reaching out to patients, supporting their needs.
Kedrion has deep roots. It could be said that, before it emerged, Kedrion began growing in the soils of Tuscany much earlier, when Guelfo Marcucci established a small pharmaceutical laboratory in Pisa in the early 1950s.
These roots grow through a series of ever larger companies focusing on blood and plasma products until 2001, when the Marcucci family consolidates them to establish Kedrion.
The foundation for the company was its partnership with the Italian Health System, providing plasma-derived medicines fractionated and produced from plasma collected by the Italian Regions.
As a tree grows and spreads, so has Kedrion. In 2004, we acquired our first collection center in the US. In 2008, we established our presence in Hungary, when we acquired the Gödöllő fractionation and production plant along with a plasma collection center. A major step was taken in 2011, with the acquisition of the Melville plant in Melville, New York, in what has become our major and fastest growing market, the United States. All our collection centers were progressively gathered under a newly formed subsidiary, KEDPLASMA, in 2012.
While Kedrion Biopharma has attracted significant outside investment and stakeholders, the Marcucci family remains in a central role. We are now 5th among the major producers of plasma-derived medicines, with five manufacturing plants and 2500 employees. By the end of this year, we anticipate having some 30 collection centers, and our products can be found in 100 countries around the world.
Today, Kedrion Biopharma remains rooted in the strong family values of the Tuscan countryside, where it is still headquartered. And now it is a truly global company committed to patients and innovation, which still pays respect to local communities, with an eye to the future of the planet.
Twenty years. The arc of our story is like a bridge – from Italy to the world. And so too is our mission: providing a bridge from donors to patients, from plasma to therapies, from despair to hope.